Dedicated to ending preventable Lyme disease suffering through technology
LymeAlarm was founded on a straightforward but urgent premise: Lyme disease is largely preventable, yet hundreds of thousands of Americans are diagnosed every year — many after months of misdiagnosis and suffering. We exist to change that.
Our platform uses a combination of environmental surveillance, biosensor data integration, AI-powered pattern recognition, and real-time alerting to help individuals, healthcare providers, and public health agencies stay ahead of Lyme disease. By detecting risk early — before symptoms appear — we can dramatically improve treatment outcomes and reduce the chronic disease burden that affects so many patients.
We are a mission-driven company that believes healthcare technology should be proactive, not reactive. With the support of our investors and healthcare partners, we are building a future where tick-borne illness is no longer a silent epidemic.
LymeAlarm's technology stack combines several cutting-edge disciplines:
Year Founded
Users Protected
Healthcare Partners
Detection Accuracy
LymeAlarm raised a $2.8M Seed Round in May 2025, led by Fortify Fund. This investment will accelerate platform development, expand our healthcare partnerships, and grow our geographic coverage to protect more communities.
Read the announcement →LymeAlarm is founded in San Francisco by Erin Dawicki and Dr. James Park after witnessing firsthand the devastating impact of late-stage Lyme disease on patients and families.
Beta version of LymeAlarm platform launches with geographic risk mapping and basic alert features. First 5,000 users onboarded across the Northeast US.
LymeAlarm integrates with major wearable health devices, enabling biosensor-based early detection. Healthcare provider dashboard launched with HIPAA compliance certification.
Raised $2.8M Seed Round led by Fortify Fund to expand coverage, improve AI detection algorithms, and grow our clinical partnership network nationwide.